v3.25.2
Transactions and Balances with Related Parties (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 12 Months Ended
Dec. 30, 2024
Oct. 31, 2024
Aug. 13, 2024
Jan. 31, 2024
Aug. 18, 2023
Mar. 22, 2023
Feb. 23, 2023
Nov. 17, 2022
Nov. 01, 2022
Sep. 15, 2022
Aug. 02, 2022
Nov. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Transactions and Balances with Related Parties [Line Items]                              
Interest rate             49.00%                
Cash consideration             $ 2,500           $ 4,540    
Deferred cash payments             $ 489                
Share capital percentage       51.00%       9.33%              
Other fee expenses       $ 20               $ 10      
Bonus amount       $ 51                      
Services expenses                         105    
Engaged in a mutual share exchange                         $ 497 $ 497  
Acquired ordinary shares (in Shares)                         35,345    
Aggregate value                         $ 288    
Aggregate values adjusted                         $ 300    
Ownership percentage                         4.99%    
Listed share price (in Dollars per share)                         $ 2.57    
Cooperation Agreement amount                         $ 63 $ 40  
Current investments               $ 1,500              
Exchange of Common Shares (in Shares)               7,692              
Outstanding share capital, percentage               9.33%              
Licensee issue price     $ 805                        
Milestones amount     $ 3,320                        
License agreement, description     (i) $50 upon a successful preclinical safety test, (ii) $100 upon first patient enrolled in phase I clinical trial, (iii) $120 upon first patient enrolled in Phase 2a clinical trial, (iv) $150 upon first patient enrolled in Phase 2b clinical trial, (v) $500 upon first patient enrolled in Phase 3 clinical trials, (vi) $800 upon approval by the U.S. Food and Drug Administration, (vii) $800 upon approval by an EU regulatory body, and (viii) $800 upon regulatory approval in any additional jurisdiction.                        
Aggregate net sales     5.00%                        
Units received (in Shares)         75,000,000 13,858     1,423 75,000,000 923   646,179    
Number of shares issued (in Shares) 1,541,096                       10,828,251 706,683  
Aggregate consideration $ 771                            
Aggregate number of the outstanding ordinary shares                         50.01%    
Jeffs’ Brands [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Services expenses                         $ 120 $ 220  
Engaged in a mutual share exchange                         $ 288    
Acquired ordinary shares (in Shares)                         13,858    
Loss on investment                         $ 17 $ 180  
Merger Agreement [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Aggregate number of the outstanding ordinary shares                         49.99%    
Initial Public Offering [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Number of units (in Shares)   684,931                          
Warrants [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Purchase price per share (in Dollars per share)   $ 4.38                     $ 4.38    
Units received (in Shares)   2,054,793                          
Warrants holds (in Shares)                         513,698    
Warrants expire date                         Oct. 31, 2029    
Warrants fair value   $ 1,399                     $ 517    
Pre-Funded Warrant [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Number of units (in Shares)   364,931                          
Purchase price per share (in Dollars per share)   $ 4.38                          
Units received (in Shares)   1,094,793                          
Number of shares issued (in Shares)                             123,504
Ordinary Share [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Number of units (in Shares)   320,000                          
Purchase price per share (in Dollars per share)   $ 4.38                          
Units received (in Shares)   320,000                     646,179    
Ordinary Share [Member] | Warrants [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Units received (in Shares)   960,000                          
Ordinary Share [Member] | Pre-Funded Warrant [Member]                              
Transactions and Balances with Related Parties [Line Items]                              
Units received (in Shares)   364,931